Faricimab: current evidence for the treatment of retinal vein occlusion
Livio Vitiello, Giuseppe Giannaccare, Enrico Borrelli, Giulia Coco, Flavia Chiosi, Filippo Lixi, Mario Troisi, Vincenzo Gagliardi, Eleonora D’Aniello, Alfonso Pellegrino, Claudio Iovino · 2026
Read Faricimab: current evidence for the treatment of retinal vein occlusion by Livio Vitiello, Giuseppe Giannaccare, Enrico Borrelli, Giulia Coco, Flavia Chiosi, Filippo Lixi, Mario Troisi, Vincenzo Gagliardi, Eleonora D’Aniello, Alfonso Pellegrino, Claudio Iovino (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13635018.txt.
Description
Livio Vitiello and ten colleagues published this 2026 review of an eye injection drug for swelling caused by blocked retinal veins. Retinal vein occlusion, a leading cause of vision loss from vessel disease, often floods the central retina with fluid. The drug, faricimab, blocks two growth signals at once. The team gathered the major phase three trials and real-world studies of the drug in branch, central, and partial vein blockages.
In the big trials, faricimab matched the standard rival drug on vision and anatomy during monthly dosing. Gains held under stretch-out schedules lasting over a year, and many patients reached longer gaps between injections. Real-world reports confirmed the anatomical gains, though vision gains varied more, especially in long-standing or stubborn cases. The safety record looked favorable overall. The authors stop short of claiming longer durability than rivals and ask for longer comparative studies.
Catalog record
| CREATOR | Livio Vitiello, Giuseppe Giannaccare, Enrico Borrelli, Giulia Coco, Flavia Chiosi, Filippo Lixi, Mario Troisi, Vincenzo Gagliardi, Eleonora D’Aniello, Alfonso Pellegrino, Claudio Iovino |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55850 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |